Westcort
Side Effects:
This medication may cause burning, stinging, itching or redness when first applied
to the skin.
This should disappear in a few days as your body adjusts to
the medication. If these effects persist or worsen, inform your doctor.
Skin infections can become worse when using this medication. Notify your
doctor if redness, swelling or irritation does not improve. Very unlikely
to occur but report promptly the following side effects: unusual weakness,
weight loss, nausea/vomiting, fainting or dizziness.
Precautions:
Do not use this medication near the eyes if you have glaucoma.
Treatment
with alclometasone, clobetasol, halobetasol propionate and augmented betamethasone
dipropionate beyond two weeks consecutively is not recommended. Do not
use if there is an infection or sores present on the area to be treated. Though
very unlikely, it is possible this medication will be absorbed into your bloodstream.
This may have undesirable consequences that may require additional corticosteroid
treatment. This is especially true for children and for those who have
used this for an extended period if they also have serious medical problems such
as serious infections, injuries or surgeries. This precaution applies for
up to one year after stopping use of this drug. Consult your doctor or pharmacist
for more details. This medication should be used cautiously during pregnancy
and only if clearly needed. Discuss the benefits and risks with your doctor.
Small amounts of this medication may appear in breast milk. Consult with
your doctor before breast-feeding. For information on Medic Alert(TM)
call 1-800-854-1166. In Canada call 1-800-668-1507. Generic
Name: CORTICOSTEROIDS - TOPICALRelated:
Westcort 0.2% Ointment - Prescription
Hydrocortisone Valerate 0.2% Ointment - Prescription
Westcort 0.2% Cream - Prescription
Hydrocortisone Valerate 0.2% Cream - Prescription 
17950slr021_westcort_lbl.pdfhttp://www.fda.gov/cder/foi/label/2003/17950slr021_westcort_lbl.pdf
corticosteroids, Westcort Cream, patients, hydrocortisone valerate, suppression,
skin, occlusion, administration, axis suppression, HPA axis, report.
The corticosteroids constitute a class of primarily synthetic steroids used topically
as anti-inflammatory and antipruritic agents.
Occlusive dressings with
hydrocortisone for up to 24 hours have not been demonstrated to increase penetration;
however, occlusion of hydrocortisone for 96 hours markedly enhances penetration.
Inflammation and/or other disease processes in the skin may increase percutaneous
absorption.
Studies performed with WESTCORT CREAM indicate that it is
in the medium range of potency as compared with other topical corticosteroids.
WESTCORT CREAM is a medium potency corticosteroid indicated for the relief of
the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses
in adult patients.
Systemic absorption of topical corticosteroids can
produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with
the potential for glucocorticosteroid insufficiency after withdrawal of treatment.
CHT-SteroidClassPotencyCOLOR.pdfhttp://www.rxfiles.ca/acrobat/CHT-SteroidClassPotencyCOLOR.pdf
potency, lotion, skin, cream, Betamethasone dipropionate, glycol, potent, Ointments,
hydrocortisone, valerate, Desoximetasone. cream section
{possibly less skin atrophy than other mid-potency agents} 5,6.
Cost =cost
for 30g/60ml (including markup/dispensing fee) in Sask.
Lowest price alternative
used where available =not interchangeable in Sask.
reserve for resistant
conditions; high potential for serious side effects (local & systemic) suitable
for short term intermittent use in severe eczematous dermatoses and psoriasis
often required for palms, soles, & scalp where thickened skin may require
prolonged Tx generally limit to OD-BID, & length of Tx.
after initial
control obtained often applied BID-QID; apply less frequent (OD-BID) if ongoing
use *Actual potency may vary considerably depending on: site of application, skin
condition, use of occlusion, and individual patient variation.
3 WHO Model
Prescibing Information: Drugs Used Dermatology, draft 1995.
|